Accumulating evidence suggests that clinically efficacious cancer immunotherapies are
driven by T cell reactivity against DNA mutation–derived neoantigens. However, among the …

Adoptive T-cell therapy (ACT) is a highly intensive immunotherapy regime that has yielded
remarkable response rates and many durable responses in clinical trials in melanoma; …

Checkpoint blockade therapies that reactivate tumour-associated T cells can induce durable
tumour control and result in the long-term survival of patients with advanced cancers 1 . …

Anti-programmed death (PD)-1 (aPD1) therapy is an effective treatment for metastatic
melanoma (MM); however, over 50% of patients progress due to resistance. We tested a first-in-…

Background Immune checkpoint inhibitors and targeted therapies have dramatically improved
outcomes in patients with advanced melanoma, but approximately half these patients will …

Dysregulated signaling through the Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways
is often the result of genetic alterations in critical components in these pathways or upstream …

The Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades are often activated by genetic
alterations in upstream signaling molecules such as receptor tyrosine kinases (RTK). Integral …

T cells in tumors—the so-called tumor infiltrating lymphocytes (TIL) have been studied
intensively over the past years. Compelling evidence point to a clinical relevance for high …

Purpose: Adoptive cell transfer therapy (ACT) based on autologous tumor-infiltrating lymphocytes
(TIL) has achieved impressive clinical results in several phase I and II trials performed …

Identification of the peptides recognized by individual T cells is important for understanding
and treating immune-related diseases. Current cytometry-based approaches are limited to …